© 2026 Zoe. All rights reserved.
Zoe is a legal information platform. Always consult the Federal Register of Legislation for authoritative text.
[2017] NSWSC 576
Supreme Court of NSW
2017-03-15
Fagan J
Original judgment source is linked above.
Solicitors: Mr Peter Li, Stephen Smart & Associates (plaintiffs) Ms Helen Gill, Norton Rose Fulbright (defendant) File Number(s): 2014/130266; 2014/130257; 2014/130258; 2014/130259; 2014/130260; 2014/130261; 2014/130262; 2014/130263; 2014/130265; 2014/130267; 2014/130268; 2014/130462; 2014/130480; 2014/131377; 2014/131391; 2014/203737 Publication restriction: Nil
Judgment
The substantive proceedings and separate question for determination
Present uncertainty of accrual of causes of action
Replies and statements for the separate hearing of the limitation defence
Accrual of the New South Wales plaintiffs' causes of action
Section 58, Limitation Act 1969
Section 60G, Limitation Act 1969
The NSW plaintiffs' witness statements
The principles of "issue waiver" of privilege
Waiver of privilege by the NSW plaintiffs
The Queensland plaintiffs
Plaintiffs' resistance to production without reasonable cause
Orders
DISCLAIMER - Every effort has been made to comply with suppression orders or statutory provisions prohibiting publication that may apply to this judgment or decision. The onus remains on any person using material in the judgment or decision to ensure that the intended use of that material does not breach any such order or provision. Further enquiries may be directed to the Registry of the Court or Tribunal in which it was generated. Decision last updated: 22 May 2017
Boorman and Ors
Glaxo Wellcome Australia Pty Ltd
[2014] QSC 303
(2015) 257 CLR 1
(2003) 27 FCR 499
(2013) 250 CLR 303
(1999) 201 CLR 1
(1992) 175 CLR 514
(2003) 127 FCR 499
[2015] HCA 33